Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

2.260 +0.070 (+3.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 575,655
Open 2.210
Bid (Size) 2.090 (100)
Ask (Size) 2.320 (1,400)
Prev. Close 2.190
Today's Range 2.095 - 2.270
52wk Range 1.650 - 4.000
Shares Outstanding 99,197,829
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
From AC Immune SA
Via GlobeNewswire

Performance

YTD
-32.7%
-32.7%
1 Month
-20.1%
-20.1%
3 Month
-21.0%
-21.0%
6 Month
-18.7%
-18.7%
1 Year
+7.6%
+7.6%

More News

Read More
News headline image
AC Immune First Quarter 2026 Financial and Corporate Updates
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
From AC Immune SA
Via GlobeNewswire
News headline image
Why AC Immune Stock Zoomed Almost 15% Higher Today ↗
Via The Motley Fool
News headline image
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
From AC Immune SA
Via GlobeNewswire
News headline image
Unusual volume stocks in Friday's session ↗
Via Chartmill
News headline image
Why Is AC Immune Stock Up Over 23% Today? ↗
Via Stocktwits
News headline image
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
From AC Immune SA
Via GlobeNewswire
News headline image
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
From AC Immune SA
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
From AC Immune SA
Via GlobeNewswire

Frequently Asked Questions

Is AC Immune SA - Common Stock publicly traded?
Yes, AC Immune SA - Common Stock is publicly traded.
What exchange does AC Immune SA - Common Stock trade on?
AC Immune SA - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AC Immune SA - Common Stock?
The ticker symbol for AC Immune SA - Common Stock is ACIU on the Nasdaq Stock Market
What is the current price of AC Immune SA - Common Stock?
The current price of AC Immune SA - Common Stock is 2.260
When was AC Immune SA - Common Stock last traded?
The last trade of AC Immune SA - Common Stock was at 06/09/26 04:00 PM ET
What is the market capitalization of AC Immune SA - Common Stock?
The market capitalization of AC Immune SA - Common Stock is 224.19M
How many shares of AC Immune SA - Common Stock are outstanding?
AC Immune SA - Common Stock has 224M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.